Effect of chronic treatment with spirapril on biochemical parameters in streptozotocin-diabetic and spontaneously hypertensive rats

Indian Journal of Experimental Biology

Volumn 35, Issue 11, 1997, Pages 1182-1186

  Parulekar, Ajit A ^a   Hakim, Zeenat S ^a   Santani, Dev D ^a   Goyal, Ramesh K ^a  

^a L M COLLEGE OF PHARMACY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; INSULIN; SPIRAPRIL; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BRADYCARDIA; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOOD INTAKE; HEART RATE; HYPERGLYCEMIA; HYPERTENSION; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; NONHUMAN; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STREPTOZOCIN DIABETES; WEIGHT REDUCTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; ENALAPRIL; FEMALE; HYPERTENSION; INSULIN RESISTANCE; RATS; RATS, INBRED SHR; RATS, WISTAR;

EID: 0031435482     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Fuh M M, Sheith S M, Wu, D A & Reaven G M, Arch Intern Med, 147 (1987) 1035.
2. Simondson D C, Diabetes Care, 11 (1988) 821.
3. Rodrigues B, Goyal R K, & Mc Neill J H, J Pharmac Expt Ther, 237 (1986) 299.
4. Goyal R K, Bangaru R A, Lakkad N B,& Rao M V, Indian J Physiol Pharmacol, 40 (3) (1996) 220.
5. Shah T S, Satia, M C, Gandhi T P, Bangaru RA, & Goyal R K, J Cardiovasc Pharmacol, 26 (1995) 6.
6. Joshi S S, Shah T S, & Goyal R K, Indian J Pharm Sci, 58(3) (1996) 100.
7. Lakkad N B, Bangaru R A, Rao M V, & Goyal R K, Pharmacol Rev Comm, 6 (1997) In press.
8. Sevak A R, & Goyal R K, Pharm Res, 34 (1996) 201.
9. Goyal R K, & Shah G B, Indian J Pharmacol, 25 (1993) 56. Abstract.
10. Hebden R A, Todd M E, Tang C, Gowen B, & Mc Neill J H, Am J Physiol, 258 (1990) R1042.
11. Dai S, & Mc Neill J H, Am J Physiol, 263 (1992) H1798.
12. Bhanot S, Bryer-Ash M, Cheung A, & Mc Neill JH, Diabetes, 43 (1994) 857.
13. Cadilhac M, & Guidicelli J F, Arch Inter de Pharmacodynamic et de therapie, 284 (1986) 114.
14. Christensen K L, Jerpersen L T, & Mulvany M J, J Hypertens, 7 (1989) 83.
15. Gans R O B, Bilo H J G, Nauta J J P, Poop-Snijders C, Heine R J, et al, Clin Sci, 80 (1991) 219.
16. Banskota N K, Taub R, Zellner K, Olson P, & King G L, Diabetes, 38 (1989) 123.
17. Baron A D, Brechtel-Hook G, Johnson A, J Hypertens, 21 (1993) 129.
18. Rodrigues B, Goyal R K, & Mc Neill JH, J Pharmcol Expt Ther, 237 (1986) 237.
19. Goyal R K, & Mc Neill J H, Fed Proc, 44 (1985) 724.
20. Faiyaz A, & Goldstein B J, Am J Physiol, 268 (1995) E932-E940.
21. Meyerovitch J, & Backer J M, J Clin Invest, 84 (1990) 976.
22. Baba T, & Ishikawa T, Drugs, 43 (1992) 484.
23. Odaya C E, Wilgis F P, Waller J F, & Oparil S, J Lab Clin Med, 102 (1983) 14.
24. Kawashima H, Nauyn Schimedberg Arch Pharmacol, 305 (1978) 123.
25. Bunag R D, Tomita T, & Saski S, Hypertension, 4 (1982) 556.
26. Funakawa S, Eur J Pharmacol, 94 (1983) 27.
27. Hayashi M, Senba S, & Saito I, Naunyn Schimedbergs Arch Pharmacol, 322 (1983) 290.
28. Ramos O L, Hypertension, 11 (S1) (1988) 118.
29. Porta M, & La Selva, Diabetologia, 30 (1987) 609.
30. Carbonnel L F, Salem M G, et al, Am J Physiol, 252 (1987) H900.
31. Tomlinson A C, Gardiner S M & Bennet T, Am J Physiol, 258 (1990)R852.
32. Savarese J J, & Berkowitz B A, Life Sci, 25 (1979) 2975.
33. Nordin C, & Gilat E, Circulation Research, 57 (1990) 28.
34. Legayle F, & Beiglemann P, Life Sci, 42 (1988) 2269.
35. Heyliger C E, Prakash A, & Mc Neill J H, Am J Physiol, 252 (1987)H540.
36. Makino N, Dhalla K S, & Dhalla N S, Am J Physiol, 253 (1987)E202.
37. Pierce G N, & Dhalla N S, Am J Physiol, 245 (1983) C241.
38. Pierce G N, & Dhalla N S, Am J Physiol, 258 (1990) H255.
39. Gill J, Br J Clin Pharmacol, 33(2) (1991) 161.
40. New M I, Roberts T N, Bierman E L, & Reader G G, Diabetes, 12 (1961) 208.
41. Paulson D J, & Light K E, Res Commun Chem Pathol Pharmacol, 33 (1987) 559.
42. Smith G D, & Pekkman J, Br Med J, 304 (1993) 431.